

VU Research Portal

Tumor characterization using radiolabeled anti-cancer drugs in NSCLC patients

Bahce, I.

2017

document version

Publisher's PDF, also known as Version of record

[Link to publication in VU Research Portal](#)

citation for published version (APA)

Bahce, I. (2017). *Tumor characterization using radiolabeled anti-cancer drugs in NSCLC patients*.

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal ?

Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

E-mail address:

vuresearchportal.ub@vu.nl

Table of Contents

Chapter 1	Introduction and outline of the thesis	9
Chapter 2	Personalizing NSCLC therapy by characterizing tumors using TKI-PET and immuno-PET	21
	<i>Lung Cancer. 2016 May 31. doi: 10.1016/j.lungcan.2016.05.025</i>	
Chapter 3	Development of [¹¹ C]erlotinib Positron Emission Tomography for <i>in vivo</i> evaluation of Epidermal Growth Factor Receptor mutational status	67
	<i>Clin Cancer Res. 2013 Jan 1;19(1):183-93.</i>	
Chapter 4	Quantitative and Simplified Analysis of ¹¹ C-Erlotinib Studies	95
	<i>J Nucl Med 2016; 57:861–866</i>	
Chapter 5	Effects of erlotinib therapy on [¹¹ C]erlotinib uptake in EGFR mutated, advanced NSCLC	115
	<i>EJNMMI Res. 2016 Dec;6(1):10. doi:10.1186/13550-016-0169-8.</i>	
Chapter 6	Detecting resistance in EGFR-mutated non-small-cell lung cancer after clonal selection through targeted therapy	141
	<i>Personalized Medicine, 2015, 12(2): 63-66</i>	
Chapter 7	Pilot study of ⁸⁹ Zr-bevacizumab positron emission tomography in patients with advanced non-small cell lung cancer	149
	<i>EJNMMI Research 2014, 4:35</i>	
Chapter 8	Discussion and summary	167
	Nederlandstalige samenvatting	177
	Dankwoord	189
	List of publications	195